A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Shipo Wu, Gongxun Zhong, Jun Zhang, Lei Shuai, Zhe Zhang, Zhiyuan Wen, Busen Wang, Zhenghao Zhao, Xiaohong Song, Yi Chen, Renqiang Liu, Ling Fu, Jinlong Zhang, Qiang Guo, Chong Wang, Yilong Yang, Ting Fang, Peng Lv, Jinliang Wang, Junjie Xu, Jianmin Li, Changming Yu, Lihua Hou (), Zhigao Bu () and Wei Chen ()
Additional contact information
Shipo Wu: Beijing Institute of Biotechnology
Gongxun Zhong: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Jun Zhang: Beijing Institute of Biotechnology
Lei Shuai: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Zhe Zhang: Beijing Institute of Biotechnology
Zhiyuan Wen: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Busen Wang: Beijing Institute of Biotechnology
Zhenghao Zhao: Beijing Institute of Biotechnology
Xiaohong Song: Beijing Institute of Biotechnology
Yi Chen: Beijing Institute of Biotechnology
Renqiang Liu: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Ling Fu: Beijing Institute of Biotechnology
Jinlong Zhang: Beijing Institute of Biotechnology
Qiang Guo: Beijing Institute of Biotechnology
Chong Wang: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Yilong Yang: Beijing Institute of Biotechnology
Ting Fang: Beijing Institute of Biotechnology
Peng Lv: Beijing Institute of Biotechnology
Jinliang Wang: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Junjie Xu: Beijing Institute of Biotechnology
Jianmin Li: Beijing Institute of Biotechnology
Changming Yu: Beijing Institute of Biotechnology
Lihua Hou: Beijing Institute of Biotechnology
Zhigao Bu: State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute
Wei Chen: Beijing Institute of Biotechnology

Nature Communications, 2020, vol. 11, issue 1, 1-7

Abstract: Abstract The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17972-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17972-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17972-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().